Effects of Lisdexamfetamine Dimesylate Treatment for ADHD on Growth

 This article was reviewed under and accepted by Ad Hoc Editor Kenneth Towbin, M.D.

 This work was supported by Shire Development, Inc.

 This article includes information from NRP104.302 Interim Analysis of a Long-Term, Open-Label, Single-Arm Study of Lisdexamfetamine (LDX), an Amphetamine Prodrug, in Children With ADHD: This study was started on November 21, 2004, and completed on March 23, 2006, and at the time of the study, industry standards and Shire standard operating procedures did not require posting of open-label studies.

 Disclosure: In the past year, Dr. Faraone has served as a consultant and on advisory boards for Eli Lilly & Company, Ortho-McNeil, and Shire, and has received research support from Eli Lilly & Company, Pfizer, Shire, and the National Institutes of Health. In previous years, Dr. Faraone has served as a consultant, on advisory boards, or on the speakers' bureau for Shire, McNeil, Janssen, Novartis, Pfizer, and Eli Lilly & Company. In previous years, he has received research support from Eli Lilly, Shire, Pfizer, and the National Institutes of Health. Dr. Glatt has received research support from the National Institutes of Health. He has received research support from, served as a consultant for, or served on the speakers' bureau for Shire Laboratories, and the National Institutes of Health. Dr. Spencer receives research support from Shire Laboratories, Cephalon, Eli Lilly & Company, GlaxoSmithKline, Janssen, McNeil Pharmaceutical, Novartis Pharmaceuticals, Pfizer, and the National Institute of Mental Health. He has served on the speakers' bureaus for Shire Laboratories, Eli Lilly & Company, GlaxoSmithKline, Janssen, McNeil Pharmaceutical, and Novartis Pharmaceuticals. He has served on the advisory boards for Shire Laboratories, Cephalon, Eli Lilly & Company, GlaxoSmithKline, Janssen, McNeil Pharmaceutical, Novartis Pharmaceuticals, and Pfizer. Dr. Kollins has received research support from Addrenex Pharmaceuticals, Comentis, Shire Pharmaceuticals, the National Institute on Drug Abuse, the National Institute of Mental Health, the National Institute of Neurological Disorders and Stroke, the National Institute of Environmental Health Services, and the Environmental Protection Agency. Dr. Kollins has served as a consultant for Addrenex Pharmaceuticals, Comentis, Shire Pharmaceuticals, and the National Institute on Drug Abuse.

PII: S0890-8567(09)00009-4

doi:10.1016/j.jaac.2009.10.003

© 2010 Published by Elsevier Inc.